Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity

Main Article Content

Linda Stein Gold
Kilian Eyerich
Howard Sofen
Pedro Herranz
Leon Kircik
Tony Bewley
Eric Wolf
Gaia Gallo
Yuxin Ding
Fan Emily Yang
Ignasi Pau-Charles
Melinda Gooderham


Lebrikizumab, efficacy, atopic dermatitis


1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

2. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

3. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

4. Yosipovitch G, et al. Br J Dermatol. 2022;186:e145.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>